Edison Investment Provides Color on Ziopharm Oncology

Edison Investment provided color on Ziopharm Oncology ZIOP. In a research report published today, Edison stressed its optimism about the company's long term outlook. In the report, Edison states, “Ziopharm has a catalyst on the horizon – the read out from the Phase III trial of palifosphamide in soft tissue sarcoma, due mid-2012. With three drugs in clinical trials, an EV of $272m suggests investors are not attributing much value to the high potential synthetic biology platform.” On Tuesday, Ziopharm lost 1.17% of its value to finish the day at $5.93.